Modulation of arachidonic acid metabolism has limited effects on the development of type I diabetes in animal models.
The therapeutic potential of modulators of arachidonic acid metabolism was probed in two animal models of type I (insulin-dependent) diabetes. Sulphasalazine treatment (50 and 400 mg/kg) did not affect diabetes development in the low dose streptozotocin model in male CD-1 mice nor in diabetes prone BB/WorD rats (100 mg/kg). Administration of acetyl salicylic acid (50 mg/kg) or BW755C (60 mg/kg) caused partial suppression of hyperglycaemia in male C57BL/6 mice after low dose streptozotocin. Twice daily treatment of BB rats with acetyl salicylic acid (5 mg/kg) did not significantly alter the course of diabetes development. We conclude that modulation of arachidonic acid metabolism has limited effects on immune-mediated diabetes.